Literature DB >> 8811199

Inhibition of arenavirus multiplication in vitro by phenotiazines.

N A Candurra1, L Maskin, E B Damonte.   

Abstract

Trifluoperazine (TFP) and chlorpromazine (CPZ), two pharmacologically active phenotiazine derivatives, were evaluated for their inhibitory activity on the replication of the arenaviruses Junin (JV), the etiological agent of Argentine hemorrhagic fever, Tacaribe virus and Pichinde virus. Both compounds achieved a concentration-dependent inhibition of viral multiplication at concentrations not affecting cell viability. The 50% inhibitory concentration (IC50) values determined by a virus yield inhibition assay for several strains of JV, including a human pathogenic strain, were in the range of 7.7-23.0 microM and the 90% inhibitory concentration (IC90) fluctuated between 16.6 and 35.2 microM. From time of addition and removal experiments, it can be concluded that CPZ inhibited an early stage in the replicative cycle of JV, probably viral entry. TFP also affected JV penetration when present soon after virus adsorption, and also interfered with a later step of viral maturation when added after 7 h of infection. The expression of viral antigens in the cytoplasm of infected cells was highly reduced in the presence of the compounds, as revealed by immunofluorescence staining, whereas no JV proteins were detected at the cell membrane. The distribution pattern of viral proteins was altered in the few cells exhibiting positive fluorescence after treatment with the phenotiazines. The TFP-induced inhibitory effect on JV multiplication was significantly reversed in the presence of 5 microM calmodulin. These data indicate that TFP and CPZ inhibit JV replication in vitro. Our findings suggest that the integrity of the actin microfilaments may be required for optimal arenavirus multiplication.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8811199     DOI: 10.1016/0166-3542(96)06956-2

Source DB:  PubMed          Journal:  Antiviral Res        ISSN: 0166-3542            Impact factor:   5.970


  12 in total

Review 1.  Novel approaches in anti-arenaviral drug development.

Authors:  Andrew M Lee; Antonella Pasquato; Stefan Kunz
Journal:  Virology       Date:  2010-12-22       Impact factor: 3.616

2.  Unbiased probing of the entire hepatitis C virus life cycle identifies clinical compounds that target multiple aspects of the infection.

Authors:  Pablo Gastaminza; Christina Whitten-Bauer; Francis V Chisari
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-07       Impact factor: 11.205

3.  A combination of low-dose chlorpromazine and neutralizing antibodies inhibits the spread of JC virus (JCV) in a tissue culture model: implications for prophylactic and therapeutic treatment of progressive multifocal leukencephalopathy.

Authors:  W J Atwood
Journal:  J Neurovirol       Date:  2001-08       Impact factor: 2.643

4.  Arenavirus Z protein as an antiviral target: virus inactivation and protein oligomerization by zinc finger-reactive compounds.

Authors:  Cybele C García; Mahmoud Djavani; Ivan Topisirovic; Katherine L B Borden; María S Salvato; Elsa B Damonte
Journal:  J Gen Virol       Date:  2006-05       Impact factor: 3.891

Review 5.  Clinically Approved Ion Channel Inhibitors Close Gates for Hepatitis C Virus and Open Doors for Drug Repurposing in Infectious Viral Diseases.

Authors:  Thomas Pietschmann
Journal:  J Virol       Date:  2017-01-03       Impact factor: 5.103

6.  A host-oriented inhibitor of Junin Argentine hemorrhagic fever virus egress.

Authors:  Jianhong Lu; Ziying Han; Yuliang Liu; Wenbo Liu; Michael S Lee; Mark A Olson; Gordon Ruthel; Bruce D Freedman; Ronald N Harty
Journal:  J Virol       Date:  2014-02-12       Impact factor: 5.103

Review 7.  Middle East Respiratory Syndrome and Severe Acute Respiratory Syndrome: Current Therapeutic Options and Potential Targets for Novel Therapies.

Authors:  Julie Dyall; Robin Gross; Jason Kindrachuk; Reed F Johnson; Gene G Olinger; Lisa E Hensley; Matthew B Frieman; Peter B Jahrling
Journal:  Drugs       Date:  2017-12       Impact factor: 9.546

Review 8.  Arenavirus Quasispecies and Their Biological Implications.

Authors:  Ana Grande-Pérez; Veronica Martin; Hector Moreno; Juan C de la Torre
Journal:  Curr Top Microbiol Immunol       Date:  2016       Impact factor: 4.291

Review 9.  Reverse genetics approaches to combat pathogenic arenaviruses.

Authors:  Juan C de la Torre
Journal:  Antiviral Res       Date:  2008-09-07       Impact factor: 5.970

Review 10.  Animal models, prophylaxis, and therapeutics for arenavirus infections.

Authors:  Eric Vela
Journal:  Viruses       Date:  2012-09-24       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.